NEWS

EUROPE WILL SEE RISE IN CHINESE INVESTMENTS IN 2019

2019-02-05T11:28:54+01:00

"Valuations up to 4-5 times will drop in the US" [McKinsey report] Chinese investment in Europe also fell 30 percent year-on-year to US$22.5bn last year, excluding from the numbers the huge US$43bn acquisition of Syngenta by ChemChina, which was completed in 2017. According to law firm Baker McKenzie and research consultancy Rhodium Group, the United [...]

EUROPE WILL SEE RISE IN CHINESE INVESTMENTS IN 20192019-02-05T11:28:54+01:00

Scape Technologies undergoes successful IPO

2019-01-09T10:11:46+01:00

Denmark-based Scape Technologies has undergone a successful IPO at Copenhagen NASDAQ on November 27, 2018. Present at the opening bell was Hans Halskov, of Across Partners, who has been instrumental in the early-stage development of the IPO, alongside FU Yuchen, Chairman of Shenzhen Maxonic Automation Co. Ltd. In 2015, Across Partners identified and negotiated the [...]

Scape Technologies undergoes successful IPO2019-01-09T10:11:46+01:00

Investment screening in Europe

2019-05-22T19:49:22+01:00

Should we have investment screening to approve or reject Chinese investments in Europe? Panel debate among experts from governments, academia, associations and advisors This was the topic of a May 20th conference organised by Think Tank Monday Morning, and Danish Chinese Business Forum, in cooperation with the foreign diplomats in Denmark. In essence, in Across [...]

Investment screening in Europe2019-05-22T19:49:22+01:00

Giant Panda idea turns to reality

2019-04-05T10:52:21+01:00

In January 2010, Hans Halskov, former consul general of the Danish Ministry of Foreign Affairs with base in Chongqing, initiated the project of getting two giant pandas to Denmark. Yesterday, after a 9 year process, the idea changed to reality, as two giant panda, Mao Sun (female) and Xing Er (male) arrived successfully to the [...]

Giant Panda idea turns to reality2019-04-05T10:52:21+01:00

81% growth in Chinese M&A transaction value in Europe Q1-3, 2018

2018-12-16T16:53:17+01:00

According to data collected by Bloomberg, in the first three quarters of 2018, companies and PE/VCs from mainland China have reached 4,303 M&A transaction deals. The overall transaction amounts sum up to USD 440,87 billion. In terms of number of deals, M&A transactions are still quite active for the first three quarters of this year [...]

81% growth in Chinese M&A transaction value in Europe Q1-3, 20182018-12-16T16:53:17+01:00

Applications accepted for exciting Internship position (Analyst)

2018-08-08T13:25:03+01:00

Job Opportunity Join an exciting opportunity to learn about M&A deals between China and Europe, and make your contributions where you can. We're accepting applications for a new Intern (Analyst) with start from September 1, 2018, for a 6-12 months term. For for more information: [ddownload id="1388"]  

Applications accepted for exciting Internship position (Analyst)2018-08-08T13:25:03+01:00

EVENT: China’s MedTech/Pharma market reforms 2018-20, – how M&A/Joint-Venture mitigate risks

2018-03-26T13:11:55+01:00

March 26, 2018 ACROSS PARTNERS hosted a Master-Class with Danish-Chinese Business Forum and Medical Device Industry Association of Denmark. The purpose was to enlighten participants about the planned disruptive reforms of China’s devices sectors, and to discuss possible solutions. The members showed huge interests in this high-growth sector and discussed the topic in the panel [...]

EVENT: China’s MedTech/Pharma market reforms 2018-20, – how M&A/Joint-Venture mitigate risks2018-03-26T13:11:55+01:00

China can benefit from M&A in European generic drug enterprises

2018-02-09T10:05:01+01:00

"Practical and Low-Risk" choice of overseas M&A in European generic drug SMEs Acquiring equity and influence in a small and medium-sized generic pharmaceutical companies has many advantages for the Chinese strategic pharmaceutical investors: 1. Clear Prospects, Controllable Risks: Compared with patented pharmaceutical products, the prospects of generic drugs are relatively clear, and the risks are [...]

China can benefit from M&A in European generic drug enterprises2018-02-09T10:05:01+01:00